ICER Report Found Baxdrostat Priced Too High
Healthcare buyers and administrators should review pricing benchmarks for hypertension drugs.
Updated on Oct. 2, 2026 in Healthcare
Live Poll
Should pharmaceutical companies be held to independent fair price benchmarks for new medications?
The Institute for Clinical and Economic Review published an evidence report evaluating hypertension treatments baxdrostat and lorundrostat. The report suggests a significant price reduction is necessary for the FDA-approved baxdrostat to align with established value benchmarks.
Why it matters
This report provides a framework for payers and health systems to evaluate cost-effectiveness and fair pricing for hypertension management. The analysis highlights the disparity between current list prices and the health improvements documented in clinical evidence.
AstraZeneca set an annual list price of $10,950 for baxdrostat, though ICER estimates that a 78-87% discount is required to meet its defined fair price range. The evaluation incorporated feedback from a four-week public comment period.
The players
Institute for Clinical and Economic Review
An independent research organization that evaluates the clinical and economic value of medical interventions for the healthcare industry.
AstraZeneca
A global biopharmaceutical company that focuses on the discovery and development of prescription medicines.
Midwest CEPAC
A regional committee that conducts public appraisals of the clinical evidence and value of health technologies.
The details
ICER conducted this analysis by measuring the health benefits and risks of interventions to establish a value-based price benchmark. While baxdrostat holds FDA approval for hypertension, researchers found insufficient evidence to directly compare its performance against the unapproved drug lorundrostat. The assessment functions as an industry guide for determining if current market pricing aligns with documented patient outcomes.
Timeline
October 1, 2026: The Institute for Clinical and Economic Review posted the revised evidence report.
October 29, 2026: The Midwest CEPAC will conduct a public meeting to review the report findings.
Market Landscape
This analysis mirrors the growing industry focus on value-based assessment models for specialty pharmaceutical products. It extends the broader transparency push established by the Inflation Reduction Act's Medicare drug-price negotiation provisions to the hypertension market.
Healthcare operators and pharmacy benefit managers should monitor this report as a benchmark for negotiating future drug coverage contracts. Factoring these value-based pricing estimates into procurement strategy may help organizations adjust their long-term clinical spending budgets.
The takeaway
This report serves as a critical signal that payers are increasingly prioritizing independent value-based evidence when determining drug coverage. Administrators should review current hypertension formulary pricing against the 78-87% discount threshold identified in the study.
What happens next
The Midwest CEPAC will hold a public meeting to review the evidence report on October 29, 2026.
Further reading
For broader trends in medical valuation and pharmaceutical policy, visit the Healthcare section.
Live Poll
Should pharmaceutical companies be held to independent fair price benchmarks for new medications?
